China has approved the $18.3 billion acquisition of Hologic by a consortium led by Blackstone and TPG. The deal, one of the largest healthcare buyouts in recent years, will take the U.S.-based leader in women’s health diagnostics and imaging private, accelerating innovation in breast cancer screening, cervical health, and molecular diagnostics.
Glimpse:
After securing regulatory clearance from Chinese antitrust authorities, Blackstone and TPG can proceed with their $18.3 billion buyout of Hologic. The transaction values Hologic at a significant premium and includes its portfolio of mammography systems, HPV testing, surgical solutions, and AI-enhanced imaging tools. The private equity firms plan to invest heavily in R&D and global expansion, particularly in emerging markets, while maintaining Hologic’s focus on women’s health technologies.
China’s antitrust regulators have granted final approval for the $18.3 billion acquisition of Hologic by a consortium led by Blackstone and TPG. The clearance removes the last major regulatory hurdle for the deal, first announced in 2025, allowing the transaction to close and take the publicly traded company private.
Hologic is a global leader in women’s health, best known for its 3D mammography systems (Selenia Dimensions), molecular diagnostics for cervical cancer and STIs (Aptima HPV assays), surgical products for gynecologic procedures, and emerging AI-powered imaging and risk-assessment tools. The company has played a key role in advancing early detection of breast and cervical cancers worldwide.
Blackstone and TPG see strong growth potential in Hologic’s portfolio, especially as demand for preventive screening rises in aging populations and emerging economies. Post-acquisition plans include increased investment in product development, geographic expansion (particularly in Asia and Latin America), and integration of AI and data analytics to enhance diagnostic accuracy and workflow efficiency.
The deal reflects continued private equity interest in healthcare, particularly in medtech segments with strong recurring revenue from consumables and services. For Hologic, going private provides greater flexibility to pursue long-term innovation without quarterly earnings pressure.
The acquisition is expected to close in the coming months, subject to final customary conditions.
“This transaction allows us to accelerate innovation and expand access to life-saving women’s health technologies on a global scale.”
By
HB Team
Related News
